PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Send a file File manager PDF Toolbox Search Help Contact



Osteoporosis Market PDF .pdf



Original filename: Osteoporosis Market - PDF.pdf
Title: Asia Medical Tourism Analysis (2008 – 2013)
Author: Publisher: Renub Research

This PDF 1.5 document has been generated by Microsoft® Office Word 2007, and has been sent on pdf-archive.com on 03/11/2015 at 07:42, from IP address 122.177.x.x. The current document download page has been viewed 407 times.
File size: 671 KB (16 pages).
Privacy: public file




Download original PDF file









Document preview


© Renub Research

Page 1 of 16

Osteoporosis is a silent disease until it is complicated by fractures that occur following minimal
trauma or, in some cases, with no trauma. Globally Osteoporosis is expected to be more than
US$ 40 Billion market by 2019. China and India together have close to 80% of osteoporosis
patients worldwide. Whereas this in case of hip fracture cases both the countries China and
India have more than 60% patients. But when we study Osteoporosis in market terms then
United States controls the highest market share followed by China and Japan. Amgen and Eli
Lilly are two dominant players in Osteoporosis drugs market.
This is the 2nd edition report on Osteoporosis by Renub Research. Report titled “Global
Osteoporosis Market, Patients, Companies & Forecast” provides a comprehensive analysis of
the current state of this market and likely future evolution over the next 5 years. This 124
page report with 89 Figures and 8 Tables studies the Worldwide Osteoporosis market from 6
view points:
1) Osteoporosis Patients & Forecast
2) Hip fracture Patients & Forecast
3) Osteoporosis Market & Forecast
4) Country Wise Osteoporosis level of Awareness, Guidelines & Policy
5) Country Wise Reimbursement of Medication
6) Company Wise Osteoporosis Drugs Sales & Forecast
All the 10 Countries studied in the report are as follows
1) India
2) China
3) Japan
4) Korea
5) Brazil
6) Russia
7) United Kingdom
8) France
9) Germany
10) United States

© Renub Research

Page 2 of 16

Worldwide Osteoporosis – Company Wise Drugs Sales Analysis (2010 – 2019)

1) Merck
2) Sanofi
3) Novartis
4) Eli Lilly
5) Amgen

Data Sources
This report is built using data and information sourced from proprietary databases, primary and
secondary research and in–house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephonic interviews with industry experts.
Secondary sources information and data has been collected from various printable and non–
printable sources like search engines, News websites, Government Websites, Trade Journals,
White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books,
Industry Portals, Industry Associations and access to more than 500 paid databases.

© Renub Research

Page 3 of 16

About Us
Renub Research

is a leading Market Research and Information Analysis Company with

centers at Noida India and Roswell USA. We have long–term experience especially in
international Business–to–Business Researches, Surveys, Business and Consulting. Throughout
the years we have acquired expertise in most market sectors, including Information Technology
(IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking,
Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer
Goods, Logistics, Governmental, Social, and Others.
Our core team is comprised of an experienced people holding graduate, post graduate and
Ph.D. degrees in Finance, Marketing, Human Resource, Bio–Technology, Medicine, Information
Technology, Environmental Science and many more. Our research help make the business
decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We
support many blue chip companies by providing them findings and perspectives across a wide
range of markets. Our research reports offer a blend of information insight, analysis and
forecasting that is essential in today’s ultra–competitive markets.

For more information on us or to view any of our sample work you can mail
us at info@renub.com

© Renub Research

Page 4 of 16

Published
By

Renub Research
1st Floor
C – 86, Sector – 10
Noida – 201301
Phone: +91–120–421–9822, 254–5750 (India)
+1–678–302–0700 (USA)
Fax : +91–120–424–9780
Email: info@renub.com
www.renub.com

© Global Osteoporosis Market, Patients, Companies & Forecast
Renub Research, 2015
Edition 2.0
All rights reserved. This publication is protected
by copyright. No part of it may be reproduced, stored
in a retrieval system or transmitted, in any form or by
any means, electronic mechanical, photocopying,
recording or otherwise without the prior written
permission of the publishers

© Renub Research

Page 5 of 16

Table of Contents
1.

Executive Summary

2.

Worldwide Osteoporosis Patients Population Analysis
2.1

Worldwide Osteoporosis Patients Population (2010 – 2019)

2.2

Worldwide Hip Fracture Patients Population (2010 – 2019)

3.

Worldwide Osteoporosis Market (2010 – 2019)

4.

Worldwide Osteoporosis Share Analysis

5.

6.

4.1

Worldwide Osteoporosis Patients Population Share (2010 – 2019)

4.2

Worldwide Hip Fracture Patients Population Share (2010 – 2019)

4.3

Worldwide Osteoporosis Market Share (2010 – 2019)

4.4

Worldwide Osteoporosis Drugs Company Market Share (2010 – 2019)

India
5.1

India Osteoporosis Patients Population (2010 – 2019)

5.2

India Hip Fracture Patients Population (2010 – 2019)

5.3

India Osteoporosis Market (2010 – 2019)

5.4

Level of Awareness

5.5

Fracture Registries

5.6

Government Policies

5.7

Guidelines

5.8

Reimbursement of Medication

China
6.1

China Osteoporosis Patients Population (2010 – 2019)

6.2

China Hip Fracture Patients Population (2010 – 2019)

6.3

China Osteoporosis Market (2010 – 2019)

6.4

Level of Awareness

6.5

Fracture Registries

6.6

Government Policies

© Renub Research

Page 6 of 16

6.7

Guidelines

6.8

Reimbursement of Medication

7.

Japan
7.1

Japan Osteoporosis Patients Population (2010 – 2019)

7.2

Japan Hip Fracture Patients Population (2010 – 2019)

7.3

Japan Osteoporosis Market (2010 – 2019)

7.4

Level of Awareness

7.5

Fracture Registries

7.6

Government Policies

7.7

Guidelines

7.8

Reimbursement of Medication

8.

Korea
8.1

Korea Osteoporosis Patients Population (2010 – 2019)

8.2

Korea Hip Fracture Patients Population (2010 – 2019)

8.3

Korea Osteoporosis Market (2010 – 2019)

8.4

Level of Awareness

8.5

Fracture Registries

8.6

Government Policies

8.7

Guidelines

8.8

Reimbursement of Medication

9.

Brazil
9.1

Brazil Osteoporosis Patients Population (2010 – 2019)

9.2

Brazil Hip Fracture Patients Population (2010 – 2019)

9.3

Brazil Osteoporosis Market (2010 – 2019)

9.4

Level of Awareness

9.5

Guidelines & Policy

9.6

Reimbursement Policy

10.

Russia

© Renub Research

Page 7 of 16

10.1

Russia Osteoporosis Patients Population (2010 – 2019)

10.2

Russia Hip Fracture Patients Population (2010 – 2019)

10.3

Russia Osteoporosis Market (2010 – 2019)

10.4

Level of Awareness

10.5

Government Policy

10.6

Guidelines

10.7

Reimbursement

11.

United Kingdom

11.1

United Kingdom Osteoporosis Patients Population (2010 – 2019)

11.2

United Kingdom Hip Fracture Patients Population (2010 – 2019)

11.3

United Kingdom Osteoporosis Market (2010 – 2019)

11.4

Guidelines

11.5

Reimbursement Policy

12.

France

12.1

France Osteoporosis Patients Population (2010 – 2019)

12.2

France Hip Fracture Patients Population (2010 – 2019)

12.3

France Osteoporosis Market (2010 – 2019)

12.4

Guidelines

12.5

Reimbursement Policy

13.

Germany

13.1

Germany Osteoporosis Patients Population (2010 – 2019)

13.2

Germany Hip Fracture Patients Population (2010 – 2019)

13.3

Germany Osteoporosis Market (2010 – 2019)

13.4

Guidelines

13.5

Reimbursement Policy

14.

United States

14.1

United States Osteoporosis Patients Population (2010 – 2019)

14.2

United States Hip Fracture Patients Population (2010 – 2019)

© Renub Research

Page 8 of 16

14.3

United States Osteoporosis Market (2010 – 2019)

14.4

Policy

14.5

Guidelines

14.6

Reimbursement Policy

15.

Growth Driver

15.1

Widespread Vitamin D Deficiency & Low Calcium Intake

15.2

Globally Increasing Ageing Population & Life Expectancy

16.

Challenges

16.1

Lack of Reimbursement / Other Restrictions for Reimbursement

16.2

Limited Access of Diagnostic Tools & Low Levels of Public and Health Professional Awareness

16.3

Lack of Government Osteoporosis Policy, Guidelines & National Health Priority in Asia Pacific

Countries
17.

Key Players Osteoporosis Drugs Sales & Forecast

17.1

Merck Osteoporosis Drugs Sales (2010 – 2019)

17.2

Sanofi Osteoporosis Drugs Sales (2010 – 2019)

17.3

Novartis Osteoporosis Drugs Sales (2010 – 2019)

17.4

Eli Lilly Osteoporosis Drugs Sales (2010 – 2019)

17.5

Amgen Osteoporosis Drugs Sales (2010 – 2019)

© Renub Research

Page 9 of 16


Related documents


PDF Document osteoporosis market pdf
PDF Document blood cancer drugs market
PDF Document sleep apnea devices market
PDF Document biosimilar market
PDF Document india outbound tourism market publisher
PDF Document asia male condom market pdf latest


Related keywords